Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Insider Kevin Mcculloch Acquires 25,000 Shares

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Kevin Mcculloch acquired 25,000 shares of the company’s stock in a transaction dated Friday, June 13th. The shares were bought at an average price of $4.38 per share, for a total transaction of $109,500.00. Following the acquisition, the insider now directly owns 1,708,585 shares of the company’s stock, valued at approximately $7,483,602.30. This trade represents a 1.48% increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through this link.

Xeris Biopharma Price Performance

Shares of NASDAQ XERS traded up $0.05 during trading on Monday, hitting $4.40. The stock had a trading volume of 1,487,345 shares, compared to its average volume of 1,983,970. The firm has a fifty day moving average of $4.55 and a two-hundred day moving average of $4.13. The company has a market capitalization of $688.09 million, a PE ratio of -9.78 and a beta of 0.71. Xeris Biopharma Holdings, Inc. has a 12 month low of $2.03 and a 12 month high of $6.07.

Xeris Biopharma (NASDAQ:XERS) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.01. The firm had revenue of $57.80 million during the quarter, compared to analysts’ expectations of $57.61 million. On average, equities analysts expect that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. Wall Street Zen downgraded Xeris Biopharma from a “buy” rating to a “hold” rating in a research note on Thursday, May 22nd. Craig Hallum boosted their price objective on Xeris Biopharma from $5.00 to $6.50 and gave the company a “buy” rating in a report on Friday, March 7th. Oppenheimer lifted their price target on shares of Xeris Biopharma from $6.00 to $7.00 and gave the company an “outperform” rating in a research report on Friday, May 9th. Leerink Partners boosted their price target on shares of Xeris Biopharma from $5.00 to $6.00 and gave the company an “outperform” rating in a research note on Friday, March 7th. Finally, HC Wainwright reiterated a “buy” rating and set a $8.00 price objective (up from $6.60) on shares of Xeris Biopharma in a report on Friday, March 7th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, Xeris Biopharma currently has an average rating of “Moderate Buy” and an average target price of $6.25.

Institutional Trading of Xeris Biopharma

A number of hedge funds have recently bought and sold shares of XERS. Rhumbline Advisers grew its stake in Xeris Biopharma by 6.3% in the 1st quarter. Rhumbline Advisers now owns 192,281 shares of the company’s stock valued at $1,056,000 after purchasing an additional 11,317 shares during the period. Strs Ohio purchased a new position in shares of Xeris Biopharma in the 1st quarter worth about $334,000. Acadian Asset Management LLC bought a new position in Xeris Biopharma during the first quarter valued at about $96,000. Caxton Associates LLP purchased a new stake in Xeris Biopharma during the first quarter worth about $170,000. Finally, Fred Alger Management LLC bought a new stake in Xeris Biopharma in the first quarter worth about $736,000. 42.75% of the stock is currently owned by institutional investors.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.